NEW YORK (GenomeWeb News) – Seattle-based biotechnology investment and management company Accelerator Corporation said today that drug discovery contract research organization PPD has joined as the sixth investor in its Accelerator III investment vehicle.
Accelerator provides resources to biotech companies, including capital financing, facilities, scientific and technical expertise and support, as well as business management and support.
The company did not disclose the value of PPD’s investment, but said that the committment brings total investment in Accelerator III to more than $27 million.
Accelerator’s life sciences partners include the Institute for Systems Biology, Amgen Ventures, Arch Venture Partners, OVP Venture Partners, Alexandria Real Estate Equities, and WRF Capital.
Accelerator is currently involved in managing three startups, including Seredigm, Recodagen, and Mirina, and the company said that it has facilitated investment and managed nine early-stage companies in the past five years.